U.S. stock market anomaly | Novo Nordisk (NVO.US) rises more than 2% Positive results from Phase III trials of new generation weight-loss drug Cagrilintide.

According to the intelegent financial news app, on Tuesday, Novo Nordisk (NVO.US) rose more than 2% to $57.12. In terms of news, on September 16th, Novo Nordisk announced that its new weight loss drug Cagrilintide showed positive results in a late-stage clinical trial. Novo Nordisk stated that an early analysis of a phase 3 trial showed that weekly injections of Cagrilintide helped patients lose an average of 11.8% of their weight after 68 weeks, compared to only 2.3% in the placebo group.